Health And Wellness Weekly Trademark Review 4 January, 2022
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
You may also be interested in...
EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.
The COVID-19 pandemic has underlined the need for less well-resourced countries to improve access to medicines, vaccines, medical devices and other health products by building their own production capacities.
Brexpiprazole could be approved as soon as 2023, and Lundbeck has pledged to support its uptake with investment in its salesforce and direct-to-consumer advertising.